Sheng Gao
Staff Affiliate - OtherAbout
Research
Publications
2024
Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study
Taylor P, Schett G, Huizinga T, Wang Q, Ibrahim F, Zhou B, Liva S, Shaik J, Xiong Y, Leu J, Panchakshari R, Loza M, Ma K, Dhatt H, Cella R, Karyekar C, Cuff C, Gao S, Fei K. Nipocalimab, an anti-FcRn monoclonal antibody, in participants with moderate to severe active rheumatoid arthritis and inadequate response or intolerance to anti-TNF therapy: results from the phase 2a IRIS-RA study. RMD Open 2024, 10: e004278. PMID: 38942592, PMCID: PMC11227837, DOI: 10.1136/rmdopen-2024-004278.Peer-Reviewed Original ResearchConceptsAnticitrullinated protein antibodiesModerate to severe active rheumatoid arthritisSevere active rheumatoid arthritisPatient-reported outcomesActive rheumatoid arthritisRheumatoid arthritisPrimary endpointAntitumour necrosis factor agentsInadequate responseModerate to severe active RAReduced serum immunoglobulin GAmerican College of Rheumatology (ACR) criteriaCirculating immune complex levelsPhase 2a studySevere active RAAnti-TNF therapyImmune complex levelsSerum inflammatory markersSerious adverse eventsStatistical significanceDAS28-CRP remissionSerum immunoglobulin GEfficacy endpointClinical improvementEfficacy benefitsModulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis
Siebert S, Coates L, Schett G, Raychaudhuri S, Chen W, Gao S, Seridi L, Chakravarty S, Shawi M, Lavie F, Sharaf M, Zimmermann M, Kollmeier A, Xu X, Rahman P, Mease P, Deodhar A. Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis. Arthritis & Rheumatology 2024, 76: 894-904. PMID: 38253404, DOI: 10.1002/art.42803.Peer-Reviewed Original ResearchBD-2 levelsTNFi-IRIL-23 signalingIL-22Clinical responseIL-17AInadequate response to tumor necrosis factor inhibitorsResponse to tumor necrosis factor inhibitorsTumor necrosis factor inhibitorsAmerican College of Rheumatology criteriaBiomarker levelsTNFi-IR patientsBD-2Serum biomarker levelsC-reactive proteinBaseline biomarker levelsActive PsAFactor inhibitorsPsA patientsWeek-24ACR20 respondersGuselkumabIL-17FRheumatology criteriaPharmacodynamic effectsCorrelation of changes in inflammatory and collagen biomarkers with durable guselkumab efficacy through 2 years in participants with active psoriatic arthritis: results from a phase III randomized controlled trial
Siebert S, Schett G, Raychaudhuri S, Guma M, Chen W, Gao S, Chakravarty S, Lavie F, Rahman P. Correlation of changes in inflammatory and collagen biomarkers with durable guselkumab efficacy through 2 years in participants with active psoriatic arthritis: results from a phase III randomized controlled trial. Therapeutic Advances In Musculoskeletal Disease 2024, 16: 1759720x241283536. PMID: 39493888, PMCID: PMC11528637, DOI: 10.1177/1759720x241283536.Peer-Reviewed Original ResearchActive psoriatic arthritisDisease activityPharmacodynamic effectsC1MActive PsADISCOVER-2Psoriatic arthritisIL-6Phase III randomized controlled trialsAmerican College of Rheumatology response criteriaBiomarker levelsBD-2 levelsC1M levelsAssociated with durable improvementsJoint disease activityOverall disease activityEffect of guselkumabSerum biomarker dataM levelsC6M levelsRandomized controlled trialsFollow-up timepointsClinical responseACR50 responseIL-17A